<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 27, 2020 (HealthDay News) — Vosoritide increases bone growth velocity in children with achondroplasia, the most common form of dwarfism, according to a study recently published in The Lancet<\/i>.<\/p>\n
Ravi Savarirayan, M.D., from the University of Melbourne in Australia, and colleagues randomly assigned 121 children diagnosed with achondroplasia (aged 5 to 18 years) to either subcutaneous injections of vosoritide or placebo for 52 weeks.<\/p>\n
The researchers found that the adjusted mean difference in annualized growth velocity between patients in the vosoritide group and placebo group was 1.57 cm\/year, favoring vosoritide. Most patients (119 people) had at least one adverse event (98 percent in both groups). None of the serious adverse events were thought to be treatment-related, and no deaths occurred.<\/p>\n
“It is not known whether final adult height will be increased, or what the harms of long-term therapy might be,” the authors write.<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including BioMarin, which manufactures vosoritide and funded the study.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n